Featured Articles

  1. How Commercial Leaders Can Optimize Their Relationships With The Board 4/30/2026

    The commercial leader/board dynamic will matter even more as pricing pressures and policy complexity increase, writes Beren Therapeutics' Bennett Smith.

  2. The East Is Ready: A New Axis Of Pharmaceutical Innovation 4/27/2026

    For Western pharmaceutical leaders, the question is no longer whether to engage Asia, but how to integrate its capabilities into core operating models. 

  3. Why Europe's Scientific Edge Still Struggles To Attract Global Capital 4/22/2026

    European biotech needs specialized capital and stronger continuity across funding stages to get to the next level, writes NUAgo Therapeutics CEO Robert Schickel, Ph.D.

  4. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

  5. Energy Shock To Clinical Cost: Mapping The Pharma Input Price Cascade 4/14/2026

    Clinical development costs are rising due to the disruption of shipping routes in the Strait of Hormuz, writes Mathini Ilancheran.

  6. Sports Playbook for Business: Leading with Speed, Clarity, and Purpose 4/10/2026

    Novo Nordisk's Aleksandar Ciric writes that leaders can apply sports principles such as speed of action, clarity, and responsiveness to be successful in life sciences.

  7. How Pharma Go-To-Market Strategy And Launch Readiness Are Transforming 4/7/2026

    Speed to market won't guarantee success in today's launch environment. Anticipating what prescribers, patients and payers will value is key, according to experts at EY.

  8. Does Biotech Need More Government Funding — Or A New Business Model? 3/30/2026

    Should government financing appreciably recede – whether through policy shifts, budget pressures, or ideological bent – what would happen to the biotech business model? To ascertain such a question, first we must look at the fundamentals of the existing model, and then understand investors (and service providers) better.

  9. The Silent Strategist: AI's "Hidden" Nudges Reshape Pipeline Strategy 3/26/2026

    With the wrong architecture in place, AI algorithms can 'nudge' biopharmaceutical developers toward unpredicted and misaligned results, according to experts.

  10. What If The U.S. Government Stopped Funding Biotech? 3/23/2026

    It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.